US2224256A - Pharmaceutical preparation - Google Patents
Pharmaceutical preparation Download PDFInfo
- Publication number
- US2224256A US2224256A US223204A US22320438A US2224256A US 2224256 A US2224256 A US 2224256A US 223204 A US223204 A US 223204A US 22320438 A US22320438 A US 22320438A US 2224256 A US2224256 A US 2224256A
- Authority
- US
- United States
- Prior art keywords
- salicylic acid
- pharmaceutical preparation
- magnesium carbonate
- acetyl salicylic
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Definitions
- the present invention relates to pharmaceutical preparations, and especially to medicinal preparations for internal use.
- An object of the invention is the increase in 5 effectiveness of a given dose, or, alternatively, the accomplishment, by means of the invention, of the same therapeutic effect with a smaller 7 dose, of a known medicinal agent, as described below.
- the invention resides in the provision of new compositions of matter in the pharmaceutical field, with particular reference to medicines for internal use.
- acetyl salicylic acid aspirin
- they may, according to the present invention, be made up to contain 3.6 grains of acetyl salicylic acid and 2 grains of normal magnesium carbonate, which tablets have substantially the same therapeutic eiIect as the hitherto known tablets containing K grains of acetyl salicylic acid made up without the normal ma nesium carbonate.
- compositions may be made by mixing equal'molecular weights of normal magnesium carbonate and acetyl salicylic acid, although it will be understood that so far 30 as the present invention is concerned, one or the other may be predominant.
- ingredients, well pulverized, are thorough- 1y mixed mechanically, are in a dry state and thereafter, with or without a binder, may be sent to the tablet machine.
- a binder such as asugar or gum may be used or starch" may be used as a binder and tablet-disintegrating agent.
- Magnesium sulfate solution may be mixed with an equivalent amount of sodium bicarbonate so- 20 lution, this mixture being allowed to stand several days in acool place. Small crystals of normal magnesium carbonate will settle out or solution and these may then be filtered, washed and. dried.
- acetyl salicylic acid tab- 25 lets made up as above described have to a marked extent the characteristic of solubility.
- the increase in therapeutic effect is due not merely to the slight laxative action of the normal mag 0 nesium carbonate but is due in large part to the ready solubility of the tablet.
- What is .claimed is A therapeutic mixture including normal magnesium carbonate and acetyl salicylic acid.
Description
Patented Dec. 10, 1940 g UNITED STATES PATENT OFFICE.
PHARMACEUTICALTREPARATION No Drawing; Application August 5, 1938, Serial No. 223,204
1 Claim. (Cl. 167-455) The present invention relates to pharmaceutical preparations, and especially to medicinal preparations for internal use.
, An object of the invention is the increase in 5 effectiveness of a given dose, or, alternatively, the accomplishment, by means of the invention, of the same therapeutic effect with a smaller 7 dose, of a known medicinal agent, as described below.
10 The invention resides in the provision of new compositions of matter in the pharmaceutical field, with particular reference to medicines for internal use.
As a practical example of the invention, it may be used as follows in the compounding of acetyl salicylic acid (aspirin) tablets. Where such tablets have hitherto been made up to contain a five grain dose, they may, according to the present invention, be made up to contain 3.6 grains of acetyl salicylic acid and 2 grains of normal magnesium carbonate, which tablets have substantially the same therapeutic eiIect as the hitherto known tablets containing K grains of acetyl salicylic acid made up without the normal ma nesium carbonate.
In general, satisfactory compositions may be made by mixing equal'molecular weights of normal magnesium carbonate and acetyl salicylic acid, although it will be understood that so far 30 as the present invention is concerned, one or the other may be predominant.
The ingredients, well pulverized, are thorough- 1y mixed mechanically, are in a dry state and thereafter, with or without a binder, may be sent to the tablet machine. If desired, a binder such as asugar or gum may be used or starch" may be used as a binder and tablet-disintegrating agent.
It will be understood, of course, that there is nothing critical in the proportions above given; they are stated by way of specific examples in the practice of the invention, which resides broadly in mixing normal magnesium carbonate 5 with acetyl salicylic acid. It is also to be observed that the invention provides not only a means broadly of increasing the therapeutic effect of a given dose, but also a means of forming, with the primary therapeutic agent, a mag- 10 nesium compound which in itself and specifically makes the composition more active therapeutically.
While the invention is not concerned with the particular method of preparing the normal magnesium carbonate (as distinguished. from the light and from the heavy magnesium carbonate) it may be made by the following known method. Magnesium sulfate solution may be mixed with an equivalent amount of sodium bicarbonate so- 20 lution, this mixture being allowed to stand several days in acool place. Small crystals of normal magnesium carbonate will settle out or solution and these may then be filtered, washed and. dried.
It will be noted that acetyl salicylic acid tab- 25 lets made up as above described have to a marked extent the characteristic of solubility. Thus the increase in therapeutic effect is due not merely to the slight laxative action of the normal mag 0 nesium carbonate but is due in large part to the ready solubility of the tablet.
What is .claimed is A therapeutic mixture including normal magnesium carbonate and acetyl salicylic acid.
wnmm if. nousnxnss.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US223204A US2224256A (en) | 1938-08-05 | 1938-08-05 | Pharmaceutical preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US223204A US2224256A (en) | 1938-08-05 | 1938-08-05 | Pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
US2224256A true US2224256A (en) | 1940-12-10 |
Family
ID=22835512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US223204A Expired - Lifetime US2224256A (en) | 1938-08-05 | 1938-08-05 | Pharmaceutical preparation |
Country Status (1)
Country | Link |
---|---|
US (1) | US2224256A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2447396A (en) * | 1946-05-17 | 1948-08-17 | Coplans Myer | Preparation of stable medicinal salts of acetylsalicylic acid |
US4294819A (en) * | 1980-08-18 | 1981-10-13 | Bristol-Myers Company | Alkaline analgesic capsule |
US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
US20030056233A1 (en) * | 1998-12-09 | 2003-03-20 | Rolf Ehrhardt | Method of treating psoriasis using anti-gamma interferon antibody |
-
1938
- 1938-08-05 US US223204A patent/US2224256A/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2447396A (en) * | 1946-05-17 | 1948-08-17 | Coplans Myer | Preparation of stable medicinal salts of acetylsalicylic acid |
US4294819A (en) * | 1980-08-18 | 1981-10-13 | Bristol-Myers Company | Alkaline analgesic capsule |
US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
US20030056233A1 (en) * | 1998-12-09 | 2003-03-20 | Rolf Ehrhardt | Method of treating psoriasis using anti-gamma interferon antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4198391A (en) | Pharmaceutical compositions | |
US3773920A (en) | Sustained release medicinal composition | |
EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
JP2016065086A5 (en) | ||
PT71727A (en) | Process for preparing a pharmaceutical composition particularly suitable for cancer treatment | |
KR850000975A (en) | Compositions based on mixtures of valproic acid and salts thereof | |
US2211485A (en) | Effervescent acetyl salicylic acid | |
JPS5948415A (en) | Long time active matrix tablet | |
US2224256A (en) | Pharmaceutical preparation | |
US3008874A (en) | Pharmaceutical compositions | |
ES370058A1 (en) | Antibiotic compositions | |
CS203036B2 (en) | Process for preparing 1,3-dibenzoyloxy-17alpha-ethinyl-7alpha-methyl-1,3,5/10/-estatrien-17beta-ole | |
US3036954A (en) | Analgesic compositions | |
CA1095411A (en) | Cardiotonic gelatin capsules | |
US2847346A (en) | Laxative compositions contaqining dioctyl sodium sulfosuccinate and 1, 8-dihydroxyanthraquinone | |
US3068147A (en) | Analgesic compositions containing o-propoxybenzamide with salicylamide or acetyl-p-aminophenol or mixtures thereof | |
US2411636A (en) | Stabilized ferrous sulfate | |
US2910403A (en) | Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides | |
US3024165A (en) | Effervescent acetyl-salicylic acid tablet | |
US2799619A (en) | Anti-excitatory compositions | |
US2918485A (en) | Dihydroxy aluminum salicylates | |
US2128741A (en) | Amine hydriodides | |
US2748052A (en) | Therapeutically active compositions containing amphetamine | |
US3348999A (en) | Compositions to enhance the learning rate and retention level in animals comprising 2-imino-5-phenyl-4-oxazolidinone and a relatively insoluble base | |
US2995598A (en) | Beta(ortho-acetoxyphenyl)propionic acid and salts thereof |